HIV/AIDS
Showing page 4 of 7 pages of list content
-
Safety and Immunogenicity of SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901 in People Living with HIV
This article's authors -
High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2
This article's authors -
COVID-19 infections post-vaccination by HIV status in the United States
This article's authors -
Tenofovir Disoproxil Fumarate and severity of COVID-19 in people with HIV infection
This article's authors -
Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020
This article's authors -
Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV
This article's authors -
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
This article's authors -
Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses
This article's authors -
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV-1
This article's authors -
Reduction in initiations of HIV treatment in South Africa during the COVID pandemic
This article's authors